US20210154180A1 - Formulation having improved ph-dependent drug-release characteristics containing esomeprazole or pharmaceutically acceptable salt thereof - Google Patents
Formulation having improved ph-dependent drug-release characteristics containing esomeprazole or pharmaceutically acceptable salt thereof Download PDFInfo
- Publication number
- US20210154180A1 US20210154180A1 US17/167,802 US202117167802A US2021154180A1 US 20210154180 A1 US20210154180 A1 US 20210154180A1 US 202117167802 A US202117167802 A US 202117167802A US 2021154180 A1 US2021154180 A1 US 2021154180A1
- Authority
- US
- United States
- Prior art keywords
- release
- tablet
- esomeprazole
- pharmaceutically acceptable
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 title claims abstract description 53
- 229960004770 esomeprazole Drugs 0.000 title claims abstract description 52
- 150000003839 salts Chemical class 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 229940079593 drug Drugs 0.000 title abstract description 12
- 239000003814 drug Substances 0.000 title abstract description 12
- 238000009472 formulation Methods 0.000 title abstract description 12
- 230000001419 dependent effect Effects 0.000 title abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 42
- 239000003826 tablet Substances 0.000 claims description 65
- 230000003511 endothelial effect Effects 0.000 claims description 57
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 46
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 46
- 239000011248 coating agent Substances 0.000 claims description 41
- 238000000576 coating method Methods 0.000 claims description 41
- 239000000463 material Substances 0.000 claims description 37
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 34
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 34
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 34
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 34
- 239000008185 minitablet Substances 0.000 claims description 22
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 21
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 20
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 19
- 239000001856 Ethyl cellulose Substances 0.000 claims description 18
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 18
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 18
- 229920001249 ethyl cellulose Polymers 0.000 claims description 18
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 16
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 16
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 12
- 108010010803 Gelatin Proteins 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000008273 gelatin Substances 0.000 claims description 9
- 229920000159 gelatin Polymers 0.000 claims description 9
- 235000019322 gelatine Nutrition 0.000 claims description 9
- 235000011852 gelatine desserts Nutrition 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 230000002496 gastric effect Effects 0.000 claims description 8
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 8
- MQEUGMWHWPYFDD-JIDHJSLPSA-N magnesium;6-methoxy-2-[(s)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound [Mg].C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C MQEUGMWHWPYFDD-JIDHJSLPSA-N 0.000 claims description 8
- 239000008188 pellet Substances 0.000 claims description 8
- 230000000968 intestinal effect Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 208000007882 Gastritis Diseases 0.000 claims description 4
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 4
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000000718 duodenal ulcer Diseases 0.000 claims description 4
- 206010013864 duodenitis Diseases 0.000 claims description 4
- 201000005917 gastric ulcer Diseases 0.000 claims description 4
- 208000000689 peptic esophagitis Diseases 0.000 claims description 4
- 208000011906 peptic ulcer disease Diseases 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- FEVPVZSYBDUVGY-YPPDDXJESA-N strontium;5-methoxy-2-[(s)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide Chemical class [Sr+2].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C FEVPVZSYBDUVGY-YPPDDXJESA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 29
- KWORUUGOSLYAGD-WLHYKHABSA-N magnesium;5-methoxy-2-[(r)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide Chemical class [Mg+2].C([S@@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-WLHYKHABSA-N 0.000 description 20
- 238000004090 dissolution Methods 0.000 description 17
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 13
- 229920003136 Eudragit® L polymer Polymers 0.000 description 10
- 229920003137 Eudragit® S polymer Polymers 0.000 description 10
- 229920003141 Eudragit® S 100 Polymers 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- 229920003139 Eudragit® L 100 Polymers 0.000 description 7
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 229960001681 croscarmellose sodium Drugs 0.000 description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 229960000381 omeprazole Drugs 0.000 description 4
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229940126409 proton pump inhibitor Drugs 0.000 description 3
- 239000000612 proton pump inhibitor Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- YBPINSCIELUFQN-UHFFFAOYSA-N COC1=C(C)C=NC(CS(=O)C2=NC3=CC=C(C)C=C3C2)=C1C Chemical compound COC1=C(C)C=NC(CS(=O)C2=NC3=CC=C(C)C=C3C2)=C1C YBPINSCIELUFQN-UHFFFAOYSA-N 0.000 description 1
- ARXGQQQJUUINDG-BQAIUKQQSA-N COC1=C(C)C=NC(C[S@](=O)C2=NC3=CC=C(C)C=C3C2)=C1C.S Chemical compound COC1=C(C)C=NC(C[S@](=O)C2=NC3=CC=C(C)C=C3C2)=C1C.S ARXGQQQJUUINDG-BQAIUKQQSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- -1 Hydroxypropyl Chemical group 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940061587 calcium behenate Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- SMBKCSPGKDEPFO-UHFFFAOYSA-L calcium;docosanoate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCCCCCC([O-])=O SMBKCSPGKDEPFO-UHFFFAOYSA-L 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 159000000008 strontium salts Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical class [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
Definitions
- the present invention relates to a novel formulation having improved pH-dependent drug release characteristics containing esomeprazole or a pharmaceutically acceptable salt thereof, and a method of preparing the same.
- Esomeprazole [(S)-5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-3H-benzoimidazole)] is a kind of proton pump inhibitor (PPI) having the structure of represented by Formula 2 as an (S)-enantiomer, among two optical isomers of omeprazole having the structure represented by Formula 1.
- PPI proton pump inhibitor
- the (R)-enantiomer is more rapidly metabolized into an inactive metabolite (not an active metabolite) and has a greater difference in metabolic rate between individuals, as compared to the (S)-enantiomer.
- the (R)-enantiomer has more side effects, poorer treatment effects and less uniform treatment rates than the (S)-enantiomer, while the (S)-enantiomer, that is, esomeprazole, has an advantage of less effect on liver metabolism, as compared to the (R)-enantiomer as well as omeprazole racemate.
- the proton pump inhibitor to which esomeprazole belongs has an advantage of inhibiting secretion of gastric acid in mammals including humans by regulating secretion of gastric acid in the last stage of the acid secretion pathway.
- the proton pump inhibitor can be used to prevent and treat gastric and esophageal reflux diseases such as reflux esophagitis, and diseases associated with gastric hyperproliferation including gastritis, duodenitis, gastric ulcer, duodenal ulcer and peptic ulcer.
- esomeprazole is easily decomposed or transformed under acidic conditions.
- oral formulations containing esomeprazole should not contact acidic gastric juice and should be delivered to the site of the gastrointestinal tract where pH is nearly neutral and rapid absorption can occur. For this reason, a formulation using a method such as forming an enteric coated layer has been actively developed.
- the present inventors have found that the pH-dependent release characteristics of esomeprazole or a pharmaceutically acceptable salt thereof can be significantly improved when an endothelial coated layer is formed on a core containing esomeprazole or a pharmaceutically acceptable salt thereof, a release-control coated layer containing a polymer composed of a methacrylic acid copolymer S and a methacrylic acid copolymer L mixed in a specific ratio is present on the endothelial coated layer, and the methacrylic acid copolymer S and the methacrylic acid copolymer L contained in the release-control coated layer are present in a certain ratio, with respect to the weight of an endothelial coated tablet or the endothelial coated layer, thereby completing the present invention.
- a pharmaceutical formulation including (a) a core containing esomeprazole or a pharmaceutically acceptable salt thereof as an active ingredient, (b) an endothelial coated layer formed on the core, and (c) a release-control coated layer formed on the endothelial coated layer, wherein an endothelial coating material contained in the endothelial coated layer, and a methacrylic acid copolymer S and a methacrylic acid copolymer L contained as release-control coating base materials in the release-control coated layer are present in a certain content ratio.
- the pharmaceutical formulation may be selected from the group consisting of a pellet, a mini-tablet (MUST), a tablet, a mixture of a pellet and a mini-tablet, and a capsule, but the present invention is not limited thereto.
- the pellet and/or the mini-tablet may be incorporated in a capsule.
- a method of preparing a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof including (a) mixing esomeprazole or a pharmaceutically acceptable salt thereof with a diluent, (b) adding a disintegrant, a binder and a lubricant to the mixture of step (a), followed by mixing, (c) dry-granulating the mixture of step (b) and then tableting to obtain a mini-tablet (MUST) or tablet, (d) endothelially coating the tableted mini-tablet or tablet obtained in step (c) using a fluidized bed dryer (FBG) and a coater, and (e) forming a release-control coated layer using a mixture containing a methacrylic acid copolymer S and a methacrylic acid copolymer L in the endothelially coated mini-tablet or tablet obtained in step (d).
- FIG. 1 shows results of a test for release characteristics regarding a pharmaceutical formulation according to the present invention wherein a mix ratio between a methacrylic acid copolymer S and a methacrylic acid copolymer L present as release-control coating base materials in a release-control coated layer is 2:1 to 3:1 (w/w), and the weight of the methacrylic acid copolymer S and the methacrylic acid copolymer L present as the release-control coating base material in the release-control coated layer is 20 to 35% (w/w), with respect to the weight of an endothelial coated tablet; and
- FIG. 2 shows results of a test for release characteristics regarding a comparative pharmaceutical formulation wherein a mix ratio between a methacrylic acid copolymer S and a methacrylic acid copolymer L present as release-control coating base materials in a release-control coated layer is 6:1 (w/w), or the weight of the methacrylic acid copolymer S and the methacrylic acid copolymer L present as the release-control coating base material in the release-control coated layer is 10 to 40% (w/w), with respect to the weight of the endothelial coated tablet.
- the present invention provides a pharmaceutical composition containing esomeprazole or a pharmaceutically acceptable salt thereof, including:
- the endothelial coated layer contains at least one selected from the group consisting of hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (PVP), low-substituted hydroxypropyl cellulose (HPC-L), starch, gelatin and ethyl cellulose (EC),
- HPMC hydroxypropyl methyl cellulose
- PVP polyvinyl pyrrolidone
- HPC-L low-substituted hydroxypropyl cellulose
- EC ethyl cellulose
- the release-control coated layer contains a mixture of a methacrylic acid copolymer S and a methacrylic acid copolymer L in a ratio of 1.5:1 to 3.5:1 (w/w), preferably 2:1 to 3:1, and
- the weight of the methacrylic acid copolymer S and the methacrylic acid copolymer L as the release-control coating base materials is 15 to 40% (w/w), preferably 20 to 35% (w/w), with respect to the weight of an endothelial coated tablet.
- the pharmaceutical formulation according to the present invention is preferably provided in the form of a pellet, a mini-tablet (MUST), a tablet, a mixture of a pellet and a mini-tablet, or a capsule, but is not limited thereto, and the pellet or mini-tablet provided may be incorporated in a capsule.
- the pharmaceutical formulation according to the present invention is almost not degraded in the stomach and starts dissolution of esomeprazole or a pharmaceutically acceptable salt thereof in the gastrointestinal tract in the pH range of 6.5 to 7.0.
- the pharmaceutical formulation starts dissolution of the esomeprazole or a pharmaceutically acceptable salt thereof at pH of 6.7 to 6.9 after a delay time of 2 hours and then finishes the dissolution after 6 hours, thus having advantages of obtaining high patient convenience and excellent therapeutic effect.
- any pharmaceutically acceptable salt of esomeprazole can be used without limitation as long as it is ordinarily used in the art, and preferred examples of the pharmaceutically acceptable salt of esomeprazole include, but are not limited to, a metal salt, such as, a magnesium (Mg) salt, a strontium (Sr) salt, a lithium salt, a sodium salt, a potassium salt or a calcium salt of esomeprazole, and an ammonium salt of esomeprazole. Most preferably, a magnesium salt or a strontium salt of esomeprazole is used.
- the esomeprazole or a pharmaceutically acceptable salt thereof may be used in the form of an anhydride or hydrate thereof.
- the core containing esomeprazole or a pharmaceutically acceptable salt thereof may also contain an appropriate amount of an ordinarily acceptable excipient, in addition to the esomeprazole or a pharmaceutically acceptable salt thereof as an active ingredient.
- the core may contain one or more excipients selected from diluents, binders, disintegrants, lubricants, surfactants, antioxidants, preservatives and stabilizers, but is not limited thereto.
- the diluent which may be contained in the core of the pharmaceutical formulation according to the present invention, may include at least one selected from the group consisting of mannitol, microcrystalline cellulose, lactose, cellulose and derivatives thereof, dibasic or tribasic calcium phosphate, erythritol, low-substituted hydroxypropyl cellulose, pregelatinized starch, sorbitol and xylitol.
- mannitol and/or microcrystalline cellulose are preferably used.
- the binder may be selected from the group consisting of hydroxypropyl cellulose (HPC), copovidone (copolymer of vinylpyrrolidone with other vinyl derivatives), hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (povidone), pregelatinized starch and low-substituted hydroxypropyl cellulose (HPC-L), but is not limited thereto. Hydroxypropyl cellulose is preferably used.
- the disintegrant may include at least one selected from the group consisting of croscarmellose sodium, corn starch, crospovidone, low-substituted hydroxypropyl cellulose (HPC-L) or pregelatinized starch, but is not limited thereto.
- croscarmellose sodium is used.
- the lubricant may include at least one selected from the group consisting of sodium stearyl fumarate, magnesium stearate, talc, polyethylene glycol, calcium behenate, calcium stearate and hydrogenated castor oil, but is not limited thereto.
- sodium stearyl fumarate is used.
- the endothelial coated layer formed on the core containing esomeprazole or a pharmaceutically acceptable salt thereof includes at least one substance selected from the group consisting of hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (PVP), low-substituted hydroxypropyl cellulose (HPC-L), starch, gelatin and ethyl cellulose (EC).
- HPMC hydroxypropyl methyl cellulose
- HPMC hydroxypropyl methyl cellulose
- endothelial coated tablet means a mini-tablet (MUST) having an endothelial coated layer formed on a core containing esomeprazole or a pharmaceutically acceptable salt thereof as an active ingredient.
- MUST mini-tablet
- the at least one substance selected from the group consisting of hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (PVP), low-substituted hydroxypropyl cellulose (HPC-L), starch, gelatin and ethyl cellulose (EC), contained in the endothelial coated layer is preferably present in a content ratio of 4.4 to 5.2% (w/w), preferably, 4.7 to 4.9% (w/w), with respect to the weight of the endothelial coated.
- the release-control coated layer formed on the endothelial coated layer contains a mixture of a methacrylic acid copolymer S and a methacrylic acid copolymer L as release-control coating base materials at a ratio of 1.5:1 to 3.5:1 (w/w), preferably 2:1 to 3:1 (w/w).
- the methacrylic acid copolymer S is an anionic copolymer containing methacrylic acid and methyl methacrylate in a ratio of about 1:2, which is sold under the trade name “Eudragit S-100” and the methacrylic acid copolymer L is an anionic copolymer containing methacrylic acid and methyl methacrylate in a ratio of about 1:1, which is sold under the trade name “Eudragit L-100”.
- release-control coated tablet means a mini-tablet (MUST) or tablet having a release-control coated layer formed on the endothelial coated layer.
- the release control coating base materials contained in the release-control coated layer namely, the methacrylic acid copolymer S and the methacrylic acid copolymer L, are present in an amount of 15 to 40% (w/w), preferably 20 to 35% (w/w), with respect to the weight of the endothelial coated tablet.
- the pharmaceutical formulation according to the present invention is characterized in that, in the release (dissolution) test using an artificial intestinal fluid (medium) having a pH of about 6.7 to 6.9 under the conditions of a number of revolutions of 75 rpm and 37° C. in accordance with the USP paddle method, 5% or less, preferably 2% or less of the esomeprazole or a pharmaceutically acceptable salt thereof is eluted after 2 hours and 90% or more, preferably 98% or more of the esomeprazole or a pharmaceutically acceptable salt thereof is eluted after 6 hours.
- the content ratio of at least one substance selected from the group consisting of hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (PVP), low-substituted hydroxypropyl cellulose (HPC-L), starch, gelatin and ethyl cellulose (EC) present in the endothelial coated layer is less than 3.5 (w/w) or higher than 8.0 (w/w)
- the esomeprazole or a pharmaceutically acceptable salt thereof begins to be eluted prior to the desired delay time according to the present invention, or the esomeprazole or a pharmaceutically acceptable salt thereof is not eluted sufficiently till a desired dissolution time.
- the amount of at least one substance selected from the group consisting of hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (PVP), low-substituted hydroxypropyl cellulose (HPC-L), starch, gelatin and ethyl cellulose (EC), with respect to the weight of the endothelial coated tablet is less than 4.4 (w/w) or higher than 5.2 (w/w)
- the esomeprazole or a pharmaceutically acceptable salt thereof begins to be eluted prior to the desired delay time, the or esomeprazole or a pharmaceutically acceptable salt thereof is not eluted sufficiently till a desired dissolution time.
- the present invention provides a method of preparing a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof as an active ingredient.
- the method of preparing a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof as an active ingredient will be described as an example in which the formulation is a mini-tablet (MUST) or a tablet.
- the pharmaceutical formulation may be prepared by the process including, but is not limited to:
- step (b) adding a disintegrant, a binder and a lubricant to the mixture of step (a), followed by mixing;
- step (c) dry-granulating the mixture of step (b) and then tableting to obtain a mini-tablet or tablet;
- step (d) endothelially coating the tableted mini-tablet or tablet obtained in step (c) using a fluidized bed dryer (FBG) and a coater; and
- FBG fluidized bed dryer
- step (e) forming a release-control coated layer using a mixture containing a methacrylic acid copolymer S and a methacrylic acid copolymer L in the endothelially coated mini-tablet or tablet obtained in step (d).
- the present invention provides the use of a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof as an active ingredient for preventing and treating gastric and esophageal reflux diseases such as reflux esophagitis, and diseases associated with gastric hyperproliferation including gastritis, duodenitis, gastric ulcer, duodenal ulcer and peptic ulcer, and a method for preventing and treating a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof as an active ingredient for preventing and treating gastric and esophageal reflux diseases such as reflux esophagitis, and diseases associated with gastric hyperproliferation including gastritis, duodenitis, gastric ulcer, duodenal ulcer and peptic ulcer, including administering the pharmaceutical formulation according to the present invention to a patient in need of the treatment.
- gastric and esophageal reflux diseases such as reflux esophagitis
- diseases associated with gastric hyperproliferation including gastritis, duodenit
- An esomeprazole magnesium salt and mannitol were mixed and granulated through a 30-mesh round sieve.
- the resulting mixture was blended with microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose and sodium stearyl fumarate in an empty blender for 15 minutes to prepare a final mixture.
- the final mixture was dry-granulated in a roller compactor and the obtained granules obtained were granulated through a 20 mesh round sieve.
- a mini tablet (MUST) having a hardness of about 1 to 2 kp and a predetermined weight of 7.5 mg was prepared by tabletting using a MUST punch having a diameter of 2.0 mm with a tabletting machine.
- composition of the final core containing an esomeprazole magnesium salt is shown in Table 2.
- the tablet was coated in accordance with the composition of Table 3 in a fluidized bed coater to obtain an endothelial coated tablet with a weight of 7.88 mg.
- the HPMC was present in the endothelial coated tablet at a content ratio of 4.82 (w/w), with respect to the weight of the endothelial coated tablet.
- Examples 1 and 2 in Table 4 relate tables wherein Eudragit S-100 and L-100 as release-control coating base materials are mixed in a ratio of 2:1 and a release-control coated layer is coated in a content ratio of 25 to 35% (w/w), with respect to the weight of an endothelial coated tablet.
- Examples 3 and 4 relate to tables wherein Eudragit S-100 and L-100 as release-control coating base materials are mixed in a ratio of 3:1 and the release-control coating base material is coated in a content ratio of 20 to 30% (w/w), with respect to the weight of the endothelial coated tablet.
- the content ratio of HPMC contained in the endothelial coated layer, with respect to the total weight of the release-control coating base materials, that is, the methacrylic acid copolymer S and the methacrylic acid copolymer L, contained in the release-control coated layer is 4.21 to 7.37 (w/w).
- Table 5 summarizes content ratios and the like, of respective ingredients in pharmaceutical formulations according to examples of the present invention.
- Comparative Examples 1 and 2 in Table 6 are compositions wherein Eudragit S-100 and Eudragit L-100 are mixed in a ratio of 2:1 and the release-control coating base material is coated in a content ratio of 10 to 40% (w/w), with respect to the weight of the endothelial coated tablet.
- Comparative Examples 3 and 4 relate to tablets wherein Eudragit S-100 and Eudragit L-100 are mixed in a ratio of 3:1 and the release-control coating base material is coated in a content ratio of 10 to 40% (w/w), with respect to the weight of the endothelial coated tablet.
- Comparative Examples 5 and 6 relate to tablets wherein Eudragit S-100 and Eudragit L-100 are mixed in a ratio of 6:1 and the release-control coating base material is coated in a content ratio of 10 to 20% (w/w), with respect to the weight of the endothelial coated tablet.
- the release-control coated layer contains a polymer composed of a methacrylic acid copolymer S and a methacrylic acid copolymer L mixed as release-control coating base materials in a ratio of 1.5:1 to 3.5:1 (w/w), preferably 2:1 to 3:1 (w/w), the weight of the release-control coating base material is 15 to 40% (w/w), preferably 20 to 35% (w/w), with respect to the weight of the tablet containing the endothelial coated layer, and the weight ratio of the release-control coating base material and HPMC in the endothelial coated layer is 3.5 to 8.0 (w/w), preferably 4.2 to 7.4 (w/w), and the weight of HPMC in the endothelial coated layer is 4.4 to 5.2% (w/w), preferably 4.7 to 4.9% (w/w), with respect to the weight of the endothelial coated tablet, the esomeprazole magnesium salt is almost not released for 2 hours, starts to be rapidly released
- Comparative Example 1 and Comparative Example 3 when the amount of the release-control coated agent used is lower than that of Examples (wherein the release-control coating base material is used at 10% or less, with respect to the endothelial coated core tablet), the effect of drug release delay in artificial intestinal fluids is poor, and as can be seen from Comparative Example 2 and Comparative Example 4, when the amount of the release-control coated agent used is higher than that of Examples (wherein the release-control coating base material is used at 40% or more, with respect to the endothelial coated core tablet), rapid drug release delay is difficult and drug release is not completed even after 6 hours, so that the drug may be excreted before being absorbed in vivo.
- the present invention relates to a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof.
- the pharmaceutical formulation according to the present invention based on considerably improved pH-dependent drug release characteristics, starts to release the esomeprazole or a pharmaceutically acceptable salt thereof at a target delay time after oral administration, continues the release for a predetermined time, and finishes the release at a predetermined time, thereby providing excellent patient convenience and excellent therapeutic effects, as compared to conventional other formulations.
Abstract
Disclosed is a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation, based on considerably improved pH-dependent drug release characteristics, starts to release the esomeprazole or a pharmaceutically acceptable salt thereof at a target delay time after oral administration, continues the release for a predetermined time, and finishes the release after a predetermined time, thereby providing excellent patient convenience and excellent therapeutic effects, as compared to conventional other formulations.
Description
- This is a continuation under the provisions of 35 USC § 120 of U.S. patent application Ser. No. 16/319,161 filed Jan. 18, 2019, which is a U.S. national phase under the provisions of 35 U.S.C. § 371 of International Patent Application No. PCT/KR17/07933 filed Jul. 24, 2017, which in turn claims priority under 35 U.S.C. § 119 of Korean Patent Application No. 10-2016-0094238 filed Jul. 25, 2016. The disclosures of such U.S. patent application Ser. No. 16/319,161, International Patent Application No. PCT/KR17/07933 and Korean Patent Application No. 10-2016-0094238 are hereby incorporated herein by reference in their respective entireties, for all purposes.
- The present invention relates to a novel formulation having improved pH-dependent drug release characteristics containing esomeprazole or a pharmaceutically acceptable salt thereof, and a method of preparing the same.
- Esomeprazole [(S)-5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-3H-benzoimidazole)] is a kind of proton pump inhibitor (PPI) having the structure of represented by
Formula 2 as an (S)-enantiomer, among two optical isomers of omeprazole having the structure represented byFormula 1. Among the two optical isomers of omeprazole, the (R)-enantiomer is more rapidly metabolized into an inactive metabolite (not an active metabolite) and has a greater difference in metabolic rate between individuals, as compared to the (S)-enantiomer. Thus, the (R)-enantiomer has more side effects, poorer treatment effects and less uniform treatment rates than the (S)-enantiomer, while the (S)-enantiomer, that is, esomeprazole, has an advantage of less effect on liver metabolism, as compared to the (R)-enantiomer as well as omeprazole racemate. - The proton pump inhibitor to which esomeprazole belongs has an advantage of inhibiting secretion of gastric acid in mammals including humans by regulating secretion of gastric acid in the last stage of the acid secretion pathway. Thus, the proton pump inhibitor can be used to prevent and treat gastric and esophageal reflux diseases such as reflux esophagitis, and diseases associated with gastric hyperproliferation including gastritis, duodenitis, gastric ulcer, duodenal ulcer and peptic ulcer.
- On the other hand, esomeprazole is easily decomposed or transformed under acidic conditions. Thus, oral formulations containing esomeprazole should not contact acidic gastric juice and should be delivered to the site of the gastrointestinal tract where pH is nearly neutral and rapid absorption can occur. For this reason, a formulation using a method such as forming an enteric coated layer has been actively developed.
- However, research on esomeprazole formulations has focused to date only on the development of enteric coating for absorption in the intestine, while preventing exposure to stomach acid in the stomach. The development on formulations, which start to be released at a specific time after the target delay time after oral administration, continue to be released for the desired period of time, and finish the release after a specific time, based on studies on pH-dependent release characteristics, was insufficient and unsatisfactory. In this context, there is an urgent and increasing need for new formulations containing esomeprazole with such improved pH-dependent release characteristics and pharmaceutically acceptable salts thereof.
- Under these technical backgrounds, the present inventors have found that the pH-dependent release characteristics of esomeprazole or a pharmaceutically acceptable salt thereof can be significantly improved when an endothelial coated layer is formed on a core containing esomeprazole or a pharmaceutically acceptable salt thereof, a release-control coated layer containing a polymer composed of a methacrylic acid copolymer S and a methacrylic acid copolymer L mixed in a specific ratio is present on the endothelial coated layer, and the methacrylic acid copolymer S and the methacrylic acid copolymer L contained in the release-control coated layer are present in a certain ratio, with respect to the weight of an endothelial coated tablet or the endothelial coated layer, thereby completing the present invention.
- Therefore, it is an object of the present invention to provide a novel pharmaceutical formulation having improved pH-dependent drug release characteristics containing esomeprazole or a pharmaceutically acceptable salt thereof, and a method of preparing the same.
- In accordance with the present invention, the above and other objects can be accomplished by the provision of a pharmaceutical formulation including (a) a core containing esomeprazole or a pharmaceutically acceptable salt thereof as an active ingredient, (b) an endothelial coated layer formed on the core, and (c) a release-control coated layer formed on the endothelial coated layer, wherein an endothelial coating material contained in the endothelial coated layer, and a methacrylic acid copolymer S and a methacrylic acid copolymer L contained as release-control coating base materials in the release-control coated layer are present in a certain content ratio.
- The pharmaceutical formulation may be selected from the group consisting of a pellet, a mini-tablet (MUST), a tablet, a mixture of a pellet and a mini-tablet, and a capsule, but the present invention is not limited thereto. The pellet and/or the mini-tablet may be incorporated in a capsule.
- In accordance with another aspect of the present invention, provided is a method of preparing a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof, including (a) mixing esomeprazole or a pharmaceutically acceptable salt thereof with a diluent, (b) adding a disintegrant, a binder and a lubricant to the mixture of step (a), followed by mixing, (c) dry-granulating the mixture of step (b) and then tableting to obtain a mini-tablet (MUST) or tablet, (d) endothelially coating the tableted mini-tablet or tablet obtained in step (c) using a fluidized bed dryer (FBG) and a coater, and (e) forming a release-control coated layer using a mixture containing a methacrylic acid copolymer S and a methacrylic acid copolymer L in the endothelially coated mini-tablet or tablet obtained in step (d).
- The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
- The above and other objects, features and other advantages of the present invention will be more clearly understood from the following detailed description taken in conjunction with the accompanying drawings, in which:
-
FIG. 1 shows results of a test for release characteristics regarding a pharmaceutical formulation according to the present invention wherein a mix ratio between a methacrylic acid copolymer S and a methacrylic acid copolymer L present as release-control coating base materials in a release-control coated layer is 2:1 to 3:1 (w/w), and the weight of the methacrylic acid copolymer S and the methacrylic acid copolymer L present as the release-control coating base material in the release-control coated layer is 20 to 35% (w/w), with respect to the weight of an endothelial coated tablet; and -
FIG. 2 shows results of a test for release characteristics regarding a comparative pharmaceutical formulation wherein a mix ratio between a methacrylic acid copolymer S and a methacrylic acid copolymer L present as release-control coating base materials in a release-control coated layer is 6:1 (w/w), or the weight of the methacrylic acid copolymer S and the methacrylic acid copolymer L present as the release-control coating base material in the release-control coated layer is 10 to 40% (w/w), with respect to the weight of the endothelial coated tablet. - Unless defined otherwise, all technical and scientific terms used herein have the same meaning as those appreciated by those skilled in the field to which the present invention pertains. In general, nomenclature used herein is well-known in the art and is ordinarily used.
- In one aspect, the present invention provides a pharmaceutical composition containing esomeprazole or a pharmaceutically acceptable salt thereof, including:
- (a) a core containing esomeprazole or a pharmaceutically acceptable salt thereof as an active ingredient;
- (b) an endothelial coated layer formed on the core; and
- (c) a release-control coated layer formed on the endothelial coated layer and containing a polymer composed of a methacrylic acid copolymer S and a methacrylic acid copolymer L mixed in a specific ratio,
- wherein the endothelial coated layer contains at least one selected from the group consisting of hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (PVP), low-substituted hydroxypropyl cellulose (HPC-L), starch, gelatin and ethyl cellulose (EC),
- the release-control coated layer contains a mixture of a methacrylic acid copolymer S and a methacrylic acid copolymer L in a ratio of 1.5:1 to 3.5:1 (w/w), preferably 2:1 to 3:1, and
- the weight of the methacrylic acid copolymer S and the methacrylic acid copolymer L as the release-control coating base materials is 15 to 40% (w/w), preferably 20 to 35% (w/w), with respect to the weight of an endothelial coated tablet.
- The pharmaceutical formulation according to the present invention is preferably provided in the form of a pellet, a mini-tablet (MUST), a tablet, a mixture of a pellet and a mini-tablet, or a capsule, but is not limited thereto, and the pellet or mini-tablet provided may be incorporated in a capsule.
- The pharmaceutical formulation according to the present invention is almost not degraded in the stomach and starts dissolution of esomeprazole or a pharmaceutically acceptable salt thereof in the gastrointestinal tract in the pH range of 6.5 to 7.0. In particular, the pharmaceutical formulation starts dissolution of the esomeprazole or a pharmaceutically acceptable salt thereof at pH of 6.7 to 6.9 after a delay time of 2 hours and then finishes the dissolution after 6 hours, thus having advantages of obtaining high patient convenience and excellent therapeutic effect.
- In the pharmaceutical formulation according to the present invention, any pharmaceutically acceptable salt of esomeprazole can be used without limitation as long as it is ordinarily used in the art, and preferred examples of the pharmaceutically acceptable salt of esomeprazole include, but are not limited to, a metal salt, such as, a magnesium (Mg) salt, a strontium (Sr) salt, a lithium salt, a sodium salt, a potassium salt or a calcium salt of esomeprazole, and an ammonium salt of esomeprazole. Most preferably, a magnesium salt or a strontium salt of esomeprazole is used.
- In addition, in the pharmaceutical formulation according to the present invention, the esomeprazole or a pharmaceutically acceptable salt thereof may be used in the form of an anhydride or hydrate thereof.
- In the pharmaceutical formulation according to the present invention, the core containing esomeprazole or a pharmaceutically acceptable salt thereof may also contain an appropriate amount of an ordinarily acceptable excipient, in addition to the esomeprazole or a pharmaceutically acceptable salt thereof as an active ingredient. Preferably, the core may contain one or more excipients selected from diluents, binders, disintegrants, lubricants, surfactants, antioxidants, preservatives and stabilizers, but is not limited thereto.
- The diluent, which may be contained in the core of the pharmaceutical formulation according to the present invention, may include at least one selected from the group consisting of mannitol, microcrystalline cellulose, lactose, cellulose and derivatives thereof, dibasic or tribasic calcium phosphate, erythritol, low-substituted hydroxypropyl cellulose, pregelatinized starch, sorbitol and xylitol. However, mannitol and/or microcrystalline cellulose are preferably used.
- The binder may be selected from the group consisting of hydroxypropyl cellulose (HPC), copovidone (copolymer of vinylpyrrolidone with other vinyl derivatives), hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (povidone), pregelatinized starch and low-substituted hydroxypropyl cellulose (HPC-L), but is not limited thereto. Hydroxypropyl cellulose is preferably used.
- The disintegrant may include at least one selected from the group consisting of croscarmellose sodium, corn starch, crospovidone, low-substituted hydroxypropyl cellulose (HPC-L) or pregelatinized starch, but is not limited thereto. Preferably, croscarmellose sodium is used.
- The lubricant may include at least one selected from the group consisting of sodium stearyl fumarate, magnesium stearate, talc, polyethylene glycol, calcium behenate, calcium stearate and hydrogenated castor oil, but is not limited thereto. Preferably, sodium stearyl fumarate is used.
- In the pharmaceutical formulation according to the present invention, the endothelial coated layer formed on the core containing esomeprazole or a pharmaceutically acceptable salt thereof includes at least one substance selected from the group consisting of hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (PVP), low-substituted hydroxypropyl cellulose (HPC-L), starch, gelatin and ethyl cellulose (EC). Preferably, hydroxypropyl methyl cellulose (HPMC) is used.
- As used herein, the term “endothelial coated tablet” means a mini-tablet (MUST) having an endothelial coated layer formed on a core containing esomeprazole or a pharmaceutically acceptable salt thereof as an active ingredient.
- The at least one substance selected from the group consisting of hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (PVP), low-substituted hydroxypropyl cellulose (HPC-L), starch, gelatin and ethyl cellulose (EC), contained in the endothelial coated layer is preferably present in a content ratio of 4.4 to 5.2% (w/w), preferably, 4.7 to 4.9% (w/w), with respect to the weight of the endothelial coated.
- In the pharmaceutical formulation according to the present invention, the release-control coated layer formed on the endothelial coated layer (which can be used interchangeably with “enteric coated layer” herein) contains a mixture of a methacrylic acid copolymer S and a methacrylic acid copolymer L as release-control coating base materials at a ratio of 1.5:1 to 3.5:1 (w/w), preferably 2:1 to 3:1 (w/w).
- The methacrylic acid copolymer S is an anionic copolymer containing methacrylic acid and methyl methacrylate in a ratio of about 1:2, which is sold under the trade name “Eudragit S-100” and the methacrylic acid copolymer L is an anionic copolymer containing methacrylic acid and methyl methacrylate in a ratio of about 1:1, which is sold under the trade name “Eudragit L-100”.
- As used herein, the term “release-control coated tablet” means a mini-tablet (MUST) or tablet having a release-control coated layer formed on the endothelial coated layer.
- In the pharmaceutical formulation according to the present invention, the release control coating base materials contained in the release-control coated layer, namely, the methacrylic acid copolymer S and the methacrylic acid copolymer L, are present in an amount of 15 to 40% (w/w), preferably 20 to 35% (w/w), with respect to the weight of the endothelial coated tablet.
- The content ratio of at least one substance selected from the group consisting of hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (PVP), low-substituted hydroxypropyl cellulose (HPC-L), starch, gelatin and ethyl cellulose (EC) present in the endothelial coated layer, with respect to the weight of the methacrylic acid copolymer S and the methacrylic acid copolymer L, is 3.5 to 8.0 (w/w), preferably 4.2 to 7.4 (w/w).
- In addition, the pharmaceutical formulation according to the present invention is characterized in that, in the release (dissolution) test using an artificial intestinal fluid (medium) having a pH of about 6.7 to 6.9 under the conditions of a number of revolutions of 75 rpm and 37° C. in accordance with the USP paddle method, 5% or less, preferably 2% or less of the esomeprazole or a pharmaceutically acceptable salt thereof is eluted after 2 hours and 90% or more, preferably 98% or more of the esomeprazole or a pharmaceutically acceptable salt thereof is eluted after 6 hours.
- When the content ratio of at least one substance selected from the group consisting of hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (PVP), low-substituted hydroxypropyl cellulose (HPC-L), starch, gelatin and ethyl cellulose (EC) present in the endothelial coated layer, with respect to the weight of the methacrylic acid copolymer S and the methacrylic acid copolymer L, as the release-control coating base material according to the present invention, is less than 3.5 (w/w) or higher than 8.0 (w/w), the esomeprazole or a pharmaceutically acceptable salt thereof begins to be eluted prior to the desired delay time according to the present invention, or the esomeprazole or a pharmaceutically acceptable salt thereof is not eluted sufficiently till a desired dissolution time.
- When the amount of at least one substance selected from the group consisting of hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (PVP), low-substituted hydroxypropyl cellulose (HPC-L), starch, gelatin and ethyl cellulose (EC), with respect to the weight of the endothelial coated tablet, is less than 4.4 (w/w) or higher than 5.2 (w/w), the esomeprazole or a pharmaceutically acceptable salt thereof begins to be eluted prior to the desired delay time, the or esomeprazole or a pharmaceutically acceptable salt thereof is not eluted sufficiently till a desired dissolution time.
- In another aspect, the present invention provides a method of preparing a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof as an active ingredient.
- Specifically, the method of preparing a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof as an active ingredient will be described as an example in which the formulation is a mini-tablet (MUST) or a tablet. Specifically, the pharmaceutical formulation may be prepared by the process including, but is not limited to:
- (a) mixing esomeprazole or a pharmaceutically acceptable salt thereof with a diluent;
- (b) adding a disintegrant, a binder and a lubricant to the mixture of step (a), followed by mixing;
- (c) dry-granulating the mixture of step (b) and then tableting to obtain a mini-tablet or tablet;
- (d) endothelially coating the tableted mini-tablet or tablet obtained in step (c) using a fluidized bed dryer (FBG) and a coater; and
- (e) forming a release-control coated layer using a mixture containing a methacrylic acid copolymer S and a methacrylic acid copolymer L in the endothelially coated mini-tablet or tablet obtained in step (d).
- In another aspect, the present invention provides the use of a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof as an active ingredient for preventing and treating gastric and esophageal reflux diseases such as reflux esophagitis, and diseases associated with gastric hyperproliferation including gastritis, duodenitis, gastric ulcer, duodenal ulcer and peptic ulcer, and a method for preventing and treating a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof as an active ingredient for preventing and treating gastric and esophageal reflux diseases such as reflux esophagitis, and diseases associated with gastric hyperproliferation including gastritis, duodenitis, gastric ulcer, duodenal ulcer and peptic ulcer, including administering the pharmaceutical formulation according to the present invention to a patient in need of the treatment.
- Hereinafter, the present invention will be described in more detail with reference to examples. However, it is obvious to those skilled in the art that these examples are provided only for illustration of the present invention and should not be construed as limiting the scope of the present invention.
- An esomeprazole magnesium salt and mannitol were mixed and granulated through a 30-mesh round sieve. The resulting mixture was blended with microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose and sodium stearyl fumarate in an empty blender for 15 minutes to prepare a final mixture. The final mixture was dry-granulated in a roller compactor and the obtained granules obtained were granulated through a 20 mesh round sieve.
- Then, a mini tablet (MUST) having a hardness of about 1 to 2 kp and a predetermined weight of 7.5 mg was prepared by tabletting using a MUST punch having a diameter of 2.0 mm with a tabletting machine.
- The composition of the final core containing an esomeprazole magnesium salt is shown in Table 2.
-
TABLE 2 Composition of core containing esomeprazole magnesium salt Weight (mg/10 Weight Ingredient Tablet) (%) Core Esomeprazole magnesium salt 21.7 28.9 Microcrystalline cellulose 15.0 20.0 Mannitol 30.5 40.7 Croscarmellose sodium 2.4 3.2 Hydroxypropyl cellulose 2.4 3.2 Sodium stearyl fumarate 3.0 4.0 Total 75.0 100.0 - Then, the tablet was coated in accordance with the composition of Table 3 in a fluidized bed coater to obtain an endothelial coated tablet with a weight of 7.88 mg.
- The HPMC was present in the endothelial coated tablet at a content ratio of 4.82 (w/w), with respect to the weight of the endothelial coated tablet.
-
TABLE 3 Composition of endothelial coated tablet Weight Weight Ingredient (mg/10 Tablet) (%) Endothelial coated Hydroxypropyl 3.8 100.0 tablet methyl cellulose Purified water (appropriate — amount) Total 78.8 100.0 - Subsequently, the above-mentioned endothelial coated tablets were coated in accordance with the composition of Table 4 in a fluidized bed coater to prepare coated tablets (release-control coated tablets) having release-control coated layers (enteric coated layers) as shown in Examples 1 to 4.
-
TABLE 4 Composition of release-control coated layer according to Examples of present invention Weight (mg /10 Tablet) Eudragit S/L = 2:1 Eudragit S/L = 3:1 Ingredient Example 1 Example 2 Example 3 Example 4 Release- Eudragit 13.3 18.6 12.0 18.0 control S-100 coated Eudragit 6.7 9.4 4.0 6.0 layer L-100 Triethyl 2.0 2.8 1.6 2.4 citrate Talc 10.0 14.0 8.0 12.0 Ethanol (appropriate (appropriate (appropriate (appropriate amount) amount) amount) amount) Distilled (appropriate (appropriate (appropriate (appropriate water amount) amount) amount) amount) Total 110.8 123.6 104.4 117.2 - Examples 1 and 2 in Table 4 relate tables wherein Eudragit S-100 and L-100 as release-control coating base materials are mixed in a ratio of 2:1 and a release-control coated layer is coated in a content ratio of 25 to 35% (w/w), with respect to the weight of an endothelial coated tablet. Examples 3 and 4 relate to tables wherein Eudragit S-100 and L-100 as release-control coating base materials are mixed in a ratio of 3:1 and the release-control coating base material is coated in a content ratio of 20 to 30% (w/w), with respect to the weight of the endothelial coated tablet. In addition, the content ratio of HPMC contained in the endothelial coated layer, with respect to the total weight of the release-control coating base materials, that is, the methacrylic acid copolymer S and the methacrylic acid copolymer L, contained in the release-control coated layer, is 4.21 to 7.37 (w/w).
- Overall, Table 5 summarizes content ratios and the like, of respective ingredients in pharmaceutical formulations according to examples of the present invention.
-
TABLE 5 Compositions and content ratios of pharmaceutical formulation according to examples of present invention Weight (mg/10 Tablet) Eudragit S/L = 2:1 Eudragit S/L = 3:1 Ingredient Example 1 Example 2 Example 3 Example 4 Weight of release-control 20 28 16 24 coating base material Weight of HPMC 3.8 3.8 3.8 3.8 Weight of endothelial 78.8 78.8 78.8 78.8 coated tablet Weight of release-control 110.8 123.6 104.4 117.2 coated tablet Weight of release-control 5.26 7.37 4.21 6.32 coating base material / weight of HPMC Weight of release- 25.38% 35.53% 20.30% 30.46% control coating base material / weight of endothelial coated tablet Weight of release-control 18.05% 22.65% 15.33% 20.48% coating base material / weight of release-control coated tablet Weight of HPMC / 4.82% 4.82% 4.82% 4.82% weight of endothelial coated tablet Weight of HPMC / 3.43% 3.07% 3.64% 3.24% weight of release- control coated tablet - Tablets of Comparative Examples 1 to 6 wherein the mini-tablet endothelially coated in accordance with the production methods of Examples 1 to 4 is provided with the release-control coated layer formed in accordance with the composition of Table 6 were prepared.
- Comparative Examples 1 and 2 in Table 6 are compositions wherein Eudragit S-100 and Eudragit L-100 are mixed in a ratio of 2:1 and the release-control coating base material is coated in a content ratio of 10 to 40% (w/w), with respect to the weight of the endothelial coated tablet. In addition, Comparative Examples 3 and 4 relate to tablets wherein Eudragit S-100 and Eudragit L-100 are mixed in a ratio of 3:1 and the release-control coating base material is coated in a content ratio of 10 to 40% (w/w), with respect to the weight of the endothelial coated tablet.
- Comparative Examples 5 and 6 relate to tablets wherein Eudragit S-100 and Eudragit L-100 are mixed in a ratio of 6:1 and the release-control coating base material is coated in a content ratio of 10 to 20% (w/w), with respect to the weight of the endothelial coated tablet.
-
TABLE 6 Composition of release-control coated layer according to Comparative Examples of present invention Weight (mg/10 Tablet) Eudragit S/L = 2:1 Eudragit S/L = 3:1 Eudragit S/L = 6:1 Ingredient Example 1 Example 2 Example 3 Example 4 Example 5 Example 6 Enteric Eudragit S-100 5.3 21.2 6.0 24.0 6.86 13.7 coating Eudragit L-100 2.7 10.8 2.0 8.0 1.14 2.3 Triethyl citrate 0.8 3.2 0.8 3.2 0.8 1.6 Talc 4.0 16.0 4.0 16.0 4.0 8.0 Ethanol (appropriate (appropriate (appropriate (appropriate (appropriate (appropriate amount) amount) amount) amount) amount) amount) Distilled water (appropriate (appropriate (appropriate (appropriate (appropriate (appropriate amount) amount) amount) amount) amount) amount) Total 91.6 130.0 91.6 130.0 91.6 104.4 - Overall, the content ratios and the like of respective ingredients of pharmaceutical formulations according to Comparative Examples of the present invention are summarized in Table 7.
-
TABLE 7 Compositions and content ratios of pharmaceutical formulations according to comparative examples of present invention Weight (mg/10 Tablet) Eudragit S/L = 2:1 Eudragit S/L = 3:1 Eudragit S/L = 6:1 Comparative Comparative Comparative Comparative Comparative Comparative Ingredient Example 1 Example 2 Example 3 Example 4 Example 5 Example 6 Weight of 8 32 8 32 8 16 release- control coating base material Weight of 3.8 3.8 3.8 3.8 3.8 3.8 HPMC Weight of 78.8 78.8 78.8 78.8 78.8 78.8 endothelial coated tablet Weight of 91.6 130 91.6 130 91.6 140.4 release- control coated tablet Weight of 2.11 8.42 2.11 8.42 2.11 4.21 release- control coating base material/ weight of HPMC Weight of 10.15% 40.61% 10.15% 40.61% 10.15% 20.30% release- control coating base material/ weight of endothelial coated tablet Weight of 8.73% 24.62% 8.73% 24.62% 8.73% 15.33% release- control coating base material/ weight of release- control coated tablet Weight of 4.82% 4.82% 4.82% 4.82% 4.82% 4.82% HPMC/ weight of endothelial coated tablet Weight of 4.15% 2.92% 4.15% 2.92% 4.15% 3.64% HPMC/ weight of release- control coating base material - The dissolution rates of esomeprazole magnesium salts were measured over time under the conditions shown in Table 8 using the formulations of Examples 1 to 4 and the formulations of Comparative Examples 1 to 6.
-
TABLE 8 Measurement conditions of dissolution rates of esomeprazole magnesium salts Dissolution conditions Dissolution fluid Artificial intestinal fluid 900 mL (pH 6.8) Apparatus USP paddle method, 75 rpm Temperature 37° C. Dissolution time Analysis at 30, 60, 90, 120, 180, 240, 300, 360 minutes Analysis conditions Analysis HPLC (Hitachi 5000 series, Japan) apparatus Detector UV spectrophotometer (measurement wavelength: 320 nm) Column Column having stainless steel tube (with inner diameter of about 4.0 mm and length of about 10 cm), filled with silica gel for liquid chromatography (particle diameter: 5 um) Mobile Sodium phosphate buffer (pH 7.3):acetonitrile: phase distilled water = 50:35:15 Flow rate 1.0 mL/min Column 30° C. temperature - The results of the measurement of the dissolution rate are shown in Tables 9 and 10 and
FIGS. 1 and 2 . As can be seen from Table 9 andFIG. 1 , in Examples 1 to 4, a drug-release delay of 2 hours or longer in the artificial intestinal fluid is possible and the release is accelerated once the release starts. - That is, it can be seen that, when the release-control coated layer contains a polymer composed of a methacrylic acid copolymer S and a methacrylic acid copolymer L mixed as release-control coating base materials in a ratio of 1.5:1 to 3.5:1 (w/w), preferably 2:1 to 3:1 (w/w), the weight of the release-control coating base material is 15 to 40% (w/w), preferably 20 to 35% (w/w), with respect to the weight of the tablet containing the endothelial coated layer, and the weight ratio of the release-control coating base material and HPMC in the endothelial coated layer is 3.5 to 8.0 (w/w), preferably 4.2 to 7.4 (w/w), and the weight of HPMC in the endothelial coated layer is 4.4 to 5.2% (w/w), preferably 4.7 to 4.9% (w/w), with respect to the weight of the endothelial coated tablet, the esomeprazole magnesium salt is almost not released for 2 hours, starts to be rapidly released after 2 hours, and 99% or higher thereof is released after 6 hours, meaning very excellent release characteristics.
- It can be seen from comparison between Example 1 and Example 3 that, as the ratio of Eudragit S-100, which is relatively insoluble in artificial intestinal fluids, increases, sufficient drug release delay is possible in spite of using a relatively small amount of release-control coating base material.
- On the other hand, as can be seen from Comparative Example 1 and Comparative Example 3, when the amount of the release-control coated agent used is lower than that of Examples (wherein the release-control coating base material is used at 10% or less, with respect to the endothelial coated core tablet), the effect of drug release delay in artificial intestinal fluids is poor, and as can be seen from Comparative Example 2 and Comparative Example 4, when the amount of the release-control coated agent used is higher than that of Examples (wherein the release-control coating base material is used at 40% or more, with respect to the endothelial coated core tablet), rapid drug release delay is difficult and drug release is not completed even after 6 hours, so that the drug may be excreted before being absorbed in vivo.
- In addition, considering Comparative Example 5 and Comparative Example 6 having a high rate of relative insoluble Eudragit S-100 in the artificial intestinal fluid, when the release-control coating base material was used at 10% or less with respect to the endothelial coated core tablet, the effect of release delay was poor, and when the release-control coating base material was used at 20% or more, disadvantageously, the drug was slowly released over a long period of time after the delay of release, and the final dissolution rate was also below 100%.
-
TABLE 9 Dissolution rates of esomeprazole magnesium salts (Examples) Dissolution rate (%) Example 1 Example 2 Example 3 Example 4 Time Standard Standard Standard Standard (min) Mean deviation Mean deviation Mean deviation Mean deviation 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 60 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 90 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 120 0.0 0.0 0.0 0.0 1.8 3.1 0.0 0.0 180 64.6 2.1 0.0 0.0 65.5 2.6 0.9 1.5 240 94.4 0.2 76.4 7.7 83.2 6.6 31.1 9.7 300 101.2 2.1 93.8 2.0 93.2 9.7 91.7 11.1 360 102.1 1.2 100.2 1.0 99.4 7.7 99.5 10.2 -
TABLE 10 Dissolution rates of esomeprazole magnesium salts (Comparative Examples) Dissolution rate (%) Comparative Comparative Comparative Comparative Comparative Comparative Example 1 Example 2 Example 3 Example 4 Example 5 Example 6 Time Standard Standard Standard Standard Standard Standard (min) Mean deviation Mean deviation Mean deviation Mean deviation Mean deviation Mean deviation 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 60 13.8 3.0 0.0 0.0 0.5 0.3 0.0 0.0 1.4 2.4 0.0 0.0 90 62.9 6.5 0.0 0.0 25.9 2.6 0.0 0.0 17.7 3.1 0.0 0.0 120 76.5 10.6 0.0 0.0 65.9 13.8 0.0 0.0 44.5 4.0 0.0 0.0 180 93.6 7.0 0.0 0.0 82.6 4.8 0.0 0.0 63.6 4.2 3.0 5.1 240 99.0 1.1 0.0 0.0 96.8 10.1 0.0 0.0 88.8 8.2 44.5 8.0 300 91.5 0.8 56.4 7.7 100.4 3.9 0.0 0.0 98.8 9.3 61.2 6.2 360 86.5 0.8 73.8 2.0 98.8 5.3 32.3 16.9 95.7 7.9 72.9 5.6 - The present invention has been described, based on preferred embodiments thereof. Those skilled in the art to which the present invention pertains will appropriate that the present invention can be implemented in modified forms without departing from the spirit and scope of the invention.
- Therefore, the embodiments disclosed above should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is defined by the appended claims rather than by the foregoing disclosure and all differences that fall into the scope of equivalents thereto should be construed as being incorporated in the present invention.
- The present invention relates to a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation according to the present invention, based on considerably improved pH-dependent drug release characteristics, starts to release the esomeprazole or a pharmaceutically acceptable salt thereof at a target delay time after oral administration, continues the release for a predetermined time, and finishes the release at a predetermined time, thereby providing excellent patient convenience and excellent therapeutic effects, as compared to conventional other formulations.
- Although specific configurations of the present invention have been described in detail, those skilled in the art will appreciate that this description is provided as preferred embodiments for illustrative purposes and should not be construed as limiting the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the accompanying claims and equivalents thereto.
Claims (9)
1. A pharmaceutical formulation comprising:
(a) a core containing esomeprazole or a pharmaceutically acceptable salt thereof as an active ingredient;
(b) an endothelial coated layer formed on the core; and
(c) a release-control coated layer formed on the endothelial coated layer,
wherein the endothelial coated layer comprises at least one selected from the group consisting of hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (PVP), low-substituted hydroxypropyl cellulose (HPC-L), starch, gelatin and ethyl cellulose (EC),
the release-control coated layer comprises a polymer in which a methacrylic acid copolymer S and a methacrylic acid copolymer L are mixed in a ratio of 1.5:1 to 3.5:1 (w/w) as release-control coating base materials, and
wherein the weight of the methacrylic acid copolymer S and the methacrylic acid copolymer L, as the release-control coating base material, is 15 to 40% (w/w), with respect to a weight of an endothelial coated tablet.
2. The pharmaceutical formulation of claim 1 , wherein a content ratio of at least one substance selected from the group consisting of hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (PVP), low-substituted hydroxypropyl cellulose (HPC-L), starch, gelatin and ethyl cellulose (EC) present in the endothelial coated layer, with respect to the weight of the methacrylic acid copolymer S and the methacrylic acid copolymer L, as the release-control coating base materials, is 3.5 to 8.0 (w/w), and
a content of at least one substance selected from the group consisting of hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (PVP), low-substituted hydroxypropyl cellulose (HPC-L), starch, gelatin and ethyl cellulose (EC), contained in the endothelial coated layer, is 4.4 to 5.2% (w/w), with respect to the weight of the endothelial coated tablet.
3. The pharmaceutical formulation of claim 1 , wherein the esomeprazole or a pharmaceutically acceptable salt thereof is an esomeprazole magnesium salt or an esomeprazole strontium salt.
4. The pharmaceutical formulation of claim 1 , wherein the esomeprazole or a pharmaceutically acceptable salt thereof is an anhydride or hydrate.
5. The pharmaceutical formulation of claim 1 , wherein the core containing esomeprazole or a pharmaceutically acceptable salt thereof further comprises at least one excipient selected from diluents, binders, disintegrants, lubricants, surfactants, antioxidants, preservatives and stabilizers.
6. The pharmaceutical formulation of claim 1 , wherein, in a release test using an artificial intestinal fluid having a pH of 6.7 to 6.9, a number of revolutions of 75 rpm and 37° C. in accordance with the USP paddle method, 5% or less of the esomeprazole or a pharmaceutically acceptable salt thereof is eluted at up to 2 hours, and at least 90% of the esomeprazole or a pharmaceutically acceptable salt thereof is eluted after 6 hours.
7. The pharmaceutical formulation of claim 1 , wherein the pharmaceutical formulation is selected from the group consisting of a pellet, a mini-tablet, a tablet, a mixture of a pellet and a mini-tablet, and a capsule.
8. A method of preventing and treating gastric and esophageal reflux diseases of reflux esophagitis, and diseases associated with gastric hyperproliferation including gastritis, duodenitis, gastric ulcer, duodenal ulcer and peptic ulcer by administering the pharmaceutical formulation of claim 1 to a subject in need thereof.
9. A method of preparing a pharmaceutical formulation of claim 1 , comprising:
(a) mixing esomeprazole or a pharmaceutically acceptable salt thereof with a diluent;
(b) adding a disintegrant, a binder and a lubricant to a mixture of step (a), followed by mixing;
(c) obtaining a mini-tablet or tablet by dry-granulating the mixture of step (b) and then tableting;
(d) endothelially coating a tableted mini-tablet or tablet obtained in step (c) using a fluidized bed dryer (FBG) and a coater; and
(e) forming a release-control coated layer using a mixture containing a methacrylic acid copolymer S and a methacrylic acid copolymer L in the endothelially coated mini-tablet or tablet obtained in step (d).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/167,802 US20210154180A1 (en) | 2016-07-25 | 2021-02-04 | Formulation having improved ph-dependent drug-release characteristics containing esomeprazole or pharmaceutically acceptable salt thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0094238 | 2016-07-25 | ||
KR1020160094238A KR101907116B1 (en) | 2016-07-25 | 2016-07-25 | Pharmaceutical Formulation with Improved pH-Dependent Drug Release Properties, Comprising Esomeprazole, or Pharmaceutically Acceptable Salt thereof |
PCT/KR2017/007933 WO2018021772A1 (en) | 2016-07-25 | 2017-07-24 | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof |
US201916319161A | 2019-01-18 | 2019-01-18 | |
US17/167,802 US20210154180A1 (en) | 2016-07-25 | 2021-02-04 | Formulation having improved ph-dependent drug-release characteristics containing esomeprazole or pharmaceutically acceptable salt thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/007933 Continuation WO2018021772A1 (en) | 2016-07-25 | 2017-07-24 | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof |
US16/319,161 Continuation US10946003B2 (en) | 2016-07-25 | 2017-07-24 | Formulation having improved pH-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210154180A1 true US20210154180A1 (en) | 2021-05-27 |
Family
ID=61017504
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/319,161 Active US10946003B2 (en) | 2016-07-25 | 2017-07-24 | Formulation having improved pH-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof |
US17/167,802 Abandoned US20210154180A1 (en) | 2016-07-25 | 2021-02-04 | Formulation having improved ph-dependent drug-release characteristics containing esomeprazole or pharmaceutically acceptable salt thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/319,161 Active US10946003B2 (en) | 2016-07-25 | 2017-07-24 | Formulation having improved pH-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof |
Country Status (11)
Country | Link |
---|---|
US (2) | US10946003B2 (en) |
EP (1) | EP3488845A4 (en) |
JP (1) | JP2019523258A (en) |
KR (1) | KR101907116B1 (en) |
CN (1) | CN109789102A (en) |
AU (1) | AU2017304029B2 (en) |
BR (1) | BR112019001423A2 (en) |
MX (1) | MX2019001032A (en) |
PH (1) | PH12019500154A1 (en) |
RU (1) | RU2716025C1 (en) |
WO (1) | WO2018021772A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA202090166A1 (en) * | 2017-09-28 | 2020-06-29 | Ханми Фарм. Ко., Лтд. | PHARMACEUTICAL COMPOSITION, INCLUDING MULTI-COMPONENT SPHEROID FORM TABLET CONTAINING ESOMEPRAZOLE AND ITS PHARMACEUTICAL ACCEPTABLE SALT, AND METHOD FOR PREPARATION |
KR102006777B1 (en) | 2018-01-29 | 2019-10-08 | 주식회사 종근당 | Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate |
KR102080023B1 (en) | 2018-01-29 | 2020-02-21 | 주식회사 종근당 | Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate |
KR102612984B1 (en) * | 2019-04-02 | 2023-12-13 | 한미약품 주식회사 | Pharmaceutical composition comprising esomeprazole, or pharmaceutically acceptable salt thereof with dual release profile |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005051362A2 (en) * | 2003-11-28 | 2005-06-09 | Ranbaxy Laboratories Limited | Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY148805A (en) * | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
JP2007524646A (en) * | 2003-07-17 | 2007-08-30 | ドクター レディズ ラボラトリーズ, インコーポレイテッド | Pharmaceutical composition having a swellable coating |
US7411804B2 (en) * | 2005-06-30 | 2008-08-12 | Seiko Epson Corporation | Integrated circuit device and electronic instrument |
US20070026071A1 (en) | 2005-07-28 | 2007-02-01 | Qpharma, Llc | Magnesium salt proton pump inhibitor dosage forms |
RU2412694C2 (en) | 2005-07-29 | 2011-02-27 | Стихтинг Гронинген Сентр фор Драг Рисерч | pH-CONTROLLED PULSE DELIVERY SYSTEMS, METHODS FOR PRODUCING AND USING THEREOF |
US20110172249A1 (en) * | 2008-09-03 | 2011-07-14 | Takeda Pharmaceutical Company Limted | Method for improving absorbability of preparation, and preparation having improved absorbability |
KR101084659B1 (en) * | 2008-12-30 | 2011-11-22 | 한미홀딩스 주식회사 | Method of priparing s-omeprazole granule and enteric coated granule thereof |
EP2319504A1 (en) * | 2009-11-07 | 2011-05-11 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical solid dosage form |
KR102060738B1 (en) * | 2012-12-13 | 2019-12-30 | 한미약품 주식회사 | Bitter taste masked pharmaceutical formulation comprising esomeprazole free base or alkali salt thereof and preparation method thereof |
-
2016
- 2016-07-25 KR KR1020160094238A patent/KR101907116B1/en active IP Right Grant
-
2017
- 2017-07-24 CN CN201780052180.XA patent/CN109789102A/en active Pending
- 2017-07-24 AU AU2017304029A patent/AU2017304029B2/en not_active Ceased
- 2017-07-24 US US16/319,161 patent/US10946003B2/en active Active
- 2017-07-24 JP JP2019503533A patent/JP2019523258A/en active Pending
- 2017-07-24 MX MX2019001032A patent/MX2019001032A/en unknown
- 2017-07-24 WO PCT/KR2017/007933 patent/WO2018021772A1/en unknown
- 2017-07-24 EP EP17834714.2A patent/EP3488845A4/en not_active Withdrawn
- 2017-07-24 RU RU2019105024A patent/RU2716025C1/en active
- 2017-07-24 BR BR112019001423-3A patent/BR112019001423A2/en active Search and Examination
-
2019
- 2019-01-21 PH PH12019500154A patent/PH12019500154A1/en unknown
-
2021
- 2021-02-04 US US17/167,802 patent/US20210154180A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005051362A2 (en) * | 2003-11-28 | 2005-06-09 | Ranbaxy Laboratories Limited | Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating |
Also Published As
Publication number | Publication date |
---|---|
KR101907116B1 (en) | 2018-10-11 |
US10946003B2 (en) | 2021-03-16 |
BR112019001423A2 (en) | 2019-05-07 |
JP2019523258A (en) | 2019-08-22 |
MX2019001032A (en) | 2019-09-10 |
WO2018021772A1 (en) | 2018-02-01 |
AU2017304029B2 (en) | 2019-10-10 |
EP3488845A4 (en) | 2020-04-08 |
RU2716025C1 (en) | 2020-03-05 |
CN109789102A (en) | 2019-05-21 |
US20190240209A1 (en) | 2019-08-08 |
PH12019500154A1 (en) | 2019-10-14 |
EP3488845A1 (en) | 2019-05-29 |
KR20180011624A (en) | 2018-02-02 |
AU2017304029A1 (en) | 2019-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210154180A1 (en) | Formulation having improved ph-dependent drug-release characteristics containing esomeprazole or pharmaceutically acceptable salt thereof | |
JPWO2005092336A1 (en) | Dissolution control preparation and production method thereof | |
JP7003279B2 (en) | Stable pharmaceutical composition containing esomeprazole and sodium bicarbonate | |
KR102146395B1 (en) | Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate having improved drug release properties | |
CN111670030A (en) | Pharmaceutical preparation containing esomeprazole and sodium bicarbonate | |
US20200368219A1 (en) | Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition | |
CN109890372B (en) | Compound capsule containing esomeprazole and preparation method thereof | |
JP2023071921A (en) | Lenalidomide oral tablet composition in various doses | |
US20220202795A1 (en) | Pharmaceutical composition comprising esomeprazole or pharmaceutically acceptable salt thereof and having double-release profile | |
US20220288045A1 (en) | Stable Pharmaceutical Composition Comprising Esomeprazole And Sodium Bicarbonate | |
KR102573842B1 (en) | Pharmaceutical composition comprising esomeprazole and sodium bicarbonate having improved drug release properties | |
EP3025707A1 (en) | A multilayer tablet comprising metformin and pioglitazone | |
US20090280175A1 (en) | Multilayer Proton Pump Inhibitor Tablets | |
KR20210012881A (en) | Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate having improved drug release properties | |
KR20090107960A (en) | Pharmaceutical formulation for treating cardiovascular disease | |
EP3331505B1 (en) | Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof | |
EA042314B1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A SPHEROID-SHAPED MULTICOMPONENT TABLET CONTAINING Esomeprazole AND ITS PHARMACEUTICALLY ACCEPTABLE SALT, AND METHOD FOR PREPARING SUCH PHARMACEUTICAL COMPOSITION | |
EA044361B1 (en) | COMPOSITE CAPSULE CONTAINING EZOMEPRAZOLE AND METHOD FOR ITS PREPARATION | |
PIMPLE et al. | FORMULATION DEVELOPMENT AND EVALUATION OF NOVEL FIXED DOSE COMBINATION OF S (-) PANTOPRAZOLE AND MOSAPRIDE CITRATE BY TABLET IN CAPSULE APPROACH | |
US20120064161A1 (en) | Modified release niacin pharmaceutical formulations | |
KR20160120503A (en) | Chrono-system formulation for Celecoxib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |